Merck's Keytruda+Herceptin+chemotherapy has positive effects in the first-line treatment of HER2-positive gastric cancer

Compilenewborn

Recently, Keytruda has won an early victory in a subgroup of patients.

The study plans to enroll 692 patients, but based on the interim analysis data of the first 264 patients, in early May of this year, the FDA has approved Keytruda+Herceptin+chemotherapy as the first-line treatment for locally advanced unresectable or metastatic HER2-positive stomach or gastroesophagus Patients with borderline (G/GEJ) cancer.

The following are the detailed results of the third phase of the KEYNOTE-811 study announced at the ASCO2021 conference:

Methods: Herceptin (trastuzumab) combined with chemotherapy is the standard treatment for HER2-positive metastatic gastric cancer and gastroesophageal junction (HER2+G/GEJ) cancer.

The study enrolled patients with untreated, unresectable or metastatic HER2+G/GEJ cancer.

Results: Among the first 264 patients enrolled, 133 patients were randomly assigned to the Keytruda+SOC group, and 131 patients were randomly assigned to the placebo+SoC group; 0.

The confirmed ORR in the Keytruda+SOC group was 74.

The median duration of response (DOR) in the Keytruda+SOC group was 10.

As of the data cutoff, 433/434 enrolled patients have received treatment (217/217 Keytruda + SOC, 216/217 placebo + SOC).

Conclusion: In the first-line treatment of HER2+ metastatic G/GEJ cancer, compared with the standard care regimen (trastuzumab+chemotherapy), adding Keytruda to the standard care regimen can significantly increase ORR, provide long-lasting remission, and is safe and reliable.

Reference source:

1.

2.